{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:40:31Z","timestamp":1784205631085,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Uveitis presumed to be secondary to <jats:italic>Mycobacterium tuberculosis<\/jats:italic> is a rare but potentially blinding condition. Difficulty in making an accurate diagnosis and the low incidence of TB uveitis (TBU) contribute to the lack of evidence regarding the best management of this condition. This systematic review aims to analyse existing research to provide a summary of the literature regarding the utility of TB therapy for the management of TBU.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This systematic review was prospectively registered on PROSPERO (PROSPERO 2021 CRD42021273379). We searched Medline, Embase and Central databases, and the search was done on 20th June 2023 with an updated literature search.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We included 55 studies and found that the heterogeneity in the methodology of these studies precluded metanalysis, and a narrative analysis was undertaken. Risk of bias analysis was undertaken using the Newcastle\u2013Ottawa scale.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Key findings of this systematic review include multiple systemic biases in the available evidence, and general lack of control for confounding variables. This results in many unanswered questions regarding the utility of TB therapy for TBU and reinforces the need for more data in this area.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-024-10288-1","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:23:05Z","timestamp":1737703385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A systemic review of the utility of antituberculosis therapy for presumed tuberculous uveitis"],"prefix":"10.1186","volume":"25","author":[{"given":"Jemma W.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginevra E. L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndell L.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Denholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"10288_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jctube.2017.01.003","volume":"7","author":"L Dalvin","year":"2017","unstructured":"Dalvin L, Smith WM. Intraocular manifestations of mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis. 2017;7:13\u201321. Elsevier Ltd.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"2","key":"10288_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ophtha.2020.06.052","volume":"128","author":"R Agrawal","year":"2021","unstructured":"Agrawal R, Testi I, Bodaghi B, Barisani-Asenbauer T, McCluskey P, Agarwal A, et al. Collaborative Ocular Tuberculosis Study Consensus Guidelines on the Management of Tubercular Uveitis\u2014Report 2: Guidelines for Initiating Antitubercular Therapy in Anterior Uveitis, Intermediate Uveitis, Panuveitis, and Retinal Vasculitis. Ophthalmology. 2021;128(2):277\u201387.","journal-title":"Ophthalmology"},{"issue":"5","key":"10288_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.5301\/ejo.5000278","volume":"23","author":"E Miserocchi","year":"2013","unstructured":"Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the Worldwide Epidemiology of Uveitis. Eur J Ophthalmol. 2013Mar 5;23(5):705\u201317.","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10288_CR4","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/archinte.1989.00390050129026","volume":"149","author":"JT Rosenbaum","year":"1989","unstructured":"Rosenbaum JT. Uveitis. An internist\u2019s view Arch Intern Med. 1989May;149(5):1173\u20136.","journal-title":"An internist\u2019s view Arch Intern Med"},{"issue":"9","key":"10288_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102351","volume":"18","author":"PJ Bertrand","year":"2019","unstructured":"Bertrand PJ, Jamilloux Y, Ecochard R, Richard-Colmant G, Gerfaud-Valentin M, Guillaud M, et al. Uveitis: Autoimmunity\u2026 and beyond. Autoimmun Rev. 2019Sep;18(9): 102351.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10288_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/ceo.13517","volume":"47","author":"CT Hart","year":"2019","unstructured":"Hart CT, Zhu EY, Crock C, Rogers SL, Lim LL. Epidemiology of uveitis in urban Australia. Clin Exp Ophthalmol. 2019;47(6):733\u201340.","journal-title":"Clin Exp Ophthalmol"},{"issue":"4 PG-475\u201380","key":"10288_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/eye.2010.235","volume":"25","author":"C Sanghvi","year":"2011","unstructured":"Sanghvi C, Bell C, Woodhead M, Hardy C, Jones N. Presumed tuberculous uveitis: diagnosis, management, and outcome. Eye (Lond). 2011;25(4 PG-475\u201380):475\u201380 Available from: NS -.","journal-title":"Eye (Lond)"},{"issue":"977","key":"10288_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1136\/pgmj.2006.052670","volume":"83","author":"PG McIntyre","year":"2007","unstructured":"McIntyre PG. How many drops of CSF is enough? Postgrad Med J. 2007;83(977):158.","journal-title":"Postgrad Med J"},{"issue":"4 PG-188\u2013193","key":"10288_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.4274\/tjo.galenos.2019.05874","volume":"49","author":"S Elangovan","year":"2019","unstructured":"Elangovan S, Govindarajan S, Mayilvakanam L, Gunasekaran N. Clinical profile and treatment response of patients with ocular inflammation due to presumed ocular tuberculosis: a retrospective study. Turk J Ophthalmol. 2019;49(4 PG-188\u2013193):188\u201393 Available from: NS -.","journal-title":"Turk J Ophthalmol"},{"issue":"1","key":"10288_CR10","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1080\/09273948.2018.1541326","volume":"28","author":"V Lloren\u00e7","year":"2020","unstructured":"Lloren\u00e7 V, Benejam G, Mesquida M, Sainz de la Maza M, Molins B, Alba C, et al. Antituberculous treatment itself might prevent visual impairment in presumed tuberculosis-related uveitis. Ocul Immunol Inflamm. 2020;28(1):103\u201310.\u00a0Available from: https:\/\/doi.org\/10.1080\/09273948.2018.1541326.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10288_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT, Atmaca LS, Becker MD, Brezin AP, et al. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509\u201316.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10288_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamaophthalmol.2017.4485","volume":"135","author":"R Agrawal","year":"2017","unstructured":"Agrawal R, Gunasekeran DV, Grant R, Agarwal A, Kon OM, Nguyen QD, et al. Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1. JAMA Ophthalmol. 2017Dec 1;135(12):1318\u201327.","journal-title":"JAMA Ophthalmol"},{"issue":"00","key":"10288_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2019.1646774","volume":"00","author":"I Testi","year":"2019","unstructured":"Testi I, Agrawal R, Mahajan S, Agarwal A, Gunasekeran DV, Raje D, et al. Tubercular Uveitis: Nuggets from Collaborative Ocular Tuberculosis Study (COTS)-1. Ocul Immunol Inflamm. 2019;00(00):1\u20139.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1080\/09273948.2019.1646774.","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10288_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.rppnen.2016.10.004","volume":"23","author":"L Figueira","year":"2017","unstructured":"Figueira L, Fonseca S, Ladeira I, Duarte R. Ocular tuberculosis: position paper on diagnosis and treatment management. Revista Portuguesa de Pneumologia (English Edition). 2017;23(1):31\u20138.\u00a0Available from:\u00a0https:\/\/doi.org\/10.1016\/j.rppnen.2016.10.004.","journal-title":"Revista Portuguesa de Pneumologia (English Edition)"},{"key":"10288_CR15","unstructured":"Elsevier Point of Care. 2023. Clinical Overview: Uveitis . https:\/\/www.clinicalkey.com.au\/#!\/content\/clinical_overview\/67-s2.0-9e71b7c5-a4f0-438c-b1ee-5028093e9786."},{"key":"10288_CR16","doi-asserted-by":"crossref","unstructured":"Mackensen F, Becker MD, Wiehler U, Max R, Dalpke A, Zimmermann S. QuantiFERON TB-Gold-A New Test Strengthening Long-Suspected Tuberculous Involvement in Serpiginous-like Choroiditis. Am J Ophthalmol. 2008Nov;146(5):761\u20136.","DOI":"10.1016\/j.ajo.2008.06.012"},{"key":"10288_CR17","doi-asserted-by":"crossref","unstructured":"Whitcup SM. 'Serpiginous Choroiditis'. In: Whitcup and Nussenblatt\u2019s Uveitis. 5th Edition. Elsevier. 2022. 368\u201377.","DOI":"10.1016\/B978-0-323-48014-7.00029-4"},{"key":"10288_CR18","doi-asserted-by":"crossref","unstructured":"Kee AR, Gonzalez-Lopez JJ, Al-Hity A, Gupta B, Lee CS, Gunasekeran DV, et al. Anti-tubercular therapy for intraocular tuberculosis: A systematic review and meta-analysis. In: Survey of Ophthalmology. USA: Elsevier; 2016. p. 628\u201353.","DOI":"10.1016\/j.survophthal.2016.03.001"},{"key":"10288_CR19","unstructured":"Agrawal R, Betzler BK, Testi I, Mahajan S, Agarwal A, Gunasekeran DV, et al. The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis. Ocul Immunol Inflamm. 2020;(cq1, 9312169 PG-1\u201311):1\u201311. Available from: NS -"},{"key":"10288_CR20","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Vol. 6, PLoS Medicine. 2009.","DOI":"10.2427\/5768"},{"key":"10288_CR21","unstructured":"Taylor JW, Denholm J, Wright G. PROSPERO International prospective register of systematic reviews Antituberculosis therapy for presumed tubercular uveitis: A systematic review of the current literature. 2021. Available from: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42021273379. Cited 2022 Oct 26."},{"key":"10288_CR22","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, LososM, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Cited 2022 Nov 14."},{"key":"10288_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ajo.2018.03.032","volume":"190","author":"O Tomkins-Netzer","year":"2018","unstructured":"Tomkins-Netzer O, Leong BCS, Zhang X, Lightman S, McCluskey PJ, Tomkins-Netzer O, et al. Effect of Antituberculous Therapy on Uveitis Associated With Latent Tuberculosis. Am J Ophthalmol. 2018;190:164\u201370.","journal-title":"Am J Ophthalmol"},{"key":"10288_CR24","doi-asserted-by":"crossref","unstructured":"Amara A, Ben Salah E, Guihot A, Fardeau C, Touitoue V, Saadoun D, et al. [Observational study of QuantiFERON R management for ocular tuberculosis diagnosis: Analysis of 244 consecutive tests]. Rev Med Interne. 2021;42(3 PG-162\u2013169):162\u20139. Available from: NS -","DOI":"10.1016\/j.revmed.2020.09.005"},{"key":"10288_CR25","doi-asserted-by":"crossref","unstructured":"Koubaa M, Smaoui F, Gargouri S, Ben Ayed H, Rekik K, Abid I, et al. [Ocular tuberculosis\u202f: A case series]. Rev Med Interne. 2018;39(5 PG-326\u2013331):326\u201331. Available from: NS -","DOI":"10.1016\/j.revmed.2018.02.014"},{"key":"10288_CR26","doi-asserted-by":"crossref","unstructured":"Bajema KL, Pakzad-Vaezi K, Hawn T, Pepple KL. Tuberculous uveitis: association between anti-tuberculous therapy and clinical response in a non-endemic country. J Ophthalmic Inflamm Infect. 2017;7(1 PG-19):19. Available from: NS -","DOI":"10.1186\/s12348-017-0137-0"},{"key":"10288_CR27","doi-asserted-by":"crossref","unstructured":"Damato EM, Dawson S, Liu X, Mukherjee C, Horsburgh J, Denniston AK, et al. A retrospective cohort study of patients treated with anti-tuberculous therapy for presumed ocular tuberculosis. J Ophthalmic Inflamm Infect. 2017;7(1 PG-23):23. Available from: NS -","DOI":"10.1186\/s12348-017-0141-4"},{"issue":"5","key":"10288_CR28","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/09273940902999349","volume":"17","author":"K Babu","year":"2009","unstructured":"Babu K, Satish V, Prakash O, Subbakrishna DK, Murthy KR. Role of the mantoux test and treatment with antitubercular therapy in a south indian patient population of presumed intraocular tuberculosis. Ocul Immunol Inflamm. 2009;17(5):307\u201311.","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10288_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1755-3768.2012.02564.x","volume":"91","author":"V Lloren\u00e7","year":"2013","unstructured":"Lloren\u00e7 V, Gonz\u00e1lez-Martin J, Keller J, Rey A, Pelegr\u00edn L, Mesquida M, et al. Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: From the tuberculin skin test to the new interferon gamma release assays. Acta Ophthalmol. 2013;91(2):99\u2013107.","journal-title":"Acta Ophthalmol"},{"key":"10288_CR30","unstructured":"Nahon-Esteve S, Martel A, Maschi C, Alketbi M, Baillif S, Tieulie N. Uveitis associated with latent tuberculosis: A comparative study of the impact of antitubercular therapy combined or not with systemic corticosteroids. Eur J Ophthalmol. 2020;(bjg, 9110772 PG-1120672120962066):1120672120962066. Available from: NS -"},{"key":"10288_CR31","doi-asserted-by":"crossref","unstructured":"Basu S, Nayak S, Padhi TR, Das T. Progressive ocular inflammation following anti-tubercular therapy for presumed ocular tuberculosis in a high-endemic setting. Eye (Lond). 2013;27(5 PG-657\u201362):657\u201362. Available from: NS -","DOI":"10.1038\/eye.2013.5"},{"key":"10288_CR32","unstructured":"Hedayatfar A, Ang M, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: A case-control study. British Journal of Ophthalmology. 2011;((Ang, Hedayatfar, Chee) Singapore National Eye Centre, Singapore, Republic of Singapore(Ang, Wong) Singapore Eye Research Institute, Singapore, Republic of Singapore(Wong, Chee) Department of Ophthalmology, Yong Yoo Lin School of Medicine, National Univer). Available from: NS -"},{"key":"10288_CR33","doi-asserted-by":"crossref","unstructured":"Brunner DR, Zweifel SA, Barthelmes D, Meier F, Boni C. Review of people with retinal vasculitis and positive QuantiFERON-TB Gold test in an area nonendemic for tuberculosis. Int Ophthalmol. 2018;38(6 PG-2389\u20132395):2389\u201395. Available from: http:\/\/www.wkap.nl\/journalhome.htm\/0165-5701 NS -.","DOI":"10.1007\/s10792-017-0739-4"},{"key":"10288_CR34","doi-asserted-by":"crossref","unstructured":"Chung CY, Li KKW. The efficacy of latent tuberculosis treatment for immunocompetent uveitis patients with a positive T-SPOT.TB test: 6-year experience in a tuberculosis endemic region. Int Ophthalmol. 2018;38(6 PG-2273\u20132282):2273\u201382. Available from: NS -","DOI":"10.1007\/s10792-017-0716-y"},{"key":"10288_CR35","doi-asserted-by":"publisher","unstructured":"Ghauri MI, Iqbal N, Riaz SU, Irfan M, Kumar A, Mukarram MS. Visual and treatment outcomes of tubercular uveitis: A prospective case series from a referral hospital in Pakistan. BMC Res Notes. 2019;12(1):10\u20133. Available from: https:\/\/doi.org\/10.1186\/s13104-019-4432-8.","DOI":"10.1186\/s13104-019-4432-8"},{"key":"10288_CR36","unstructured":"Ang L, Kee A, Yeo TH, Dinesh VG, Ho SL, Teoh SC, et al. Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. Int Ophthalmol. 2018;38(1 PG-11\u201318):11\u20138. Available from: NS -"},{"key":"10288_CR37","doi-asserted-by":"crossref","unstructured":"Anibarro L, Cortes E, Chouza A, Parafita-Fernandez A, Garcia JC, Pena A, et al. Early treatment of tuberculous uveitis improves visual outcome: a 10-year cohort study. Infection. 2018;46(4 PG-549\u2013554):549\u201354. Available from: NS -","DOI":"10.1007\/s15010-018-1161-1"},{"key":"10288_CR38","doi-asserted-by":"crossref","unstructured":"Urzua CA, Lantigua Y, Abuauad S, Liberman P, Berger O, Sabat P, et al. Clinical Features and Prognostic Factors in Presumed Ocular Tuberculosis. Curr Eye Res. 2017;42(7 PG-1029\u20131034):1029\u201334. Available from: NS -","DOI":"10.1080\/02713683.2016.1266663"},{"key":"10288_CR39","doi-asserted-by":"publisher","unstructured":"La Distia Nora R, Van Velthoven MEJ, Ten Dam-Van Loon NH, Misotten T, Bakker M, Van Hagen MP, et al. Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis. Am J Ophthalmol. 2014;157(4):754\u201361. Available from: https:\/\/doi.org\/10.1016\/j.ajo.2013.11.013.","DOI":"10.1016\/j.ajo.2013.11.013"},{"issue":"2","key":"10288_CR40","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s15010-013-0554-4","volume":"42","author":"MS Tognon","year":"2014","unstructured":"Tognon MS, Fiscon M, Mirabelli P, Graziani G, Peracchi M, Sattin A, et al. Tuberculosis of the eye in Italy: A forgotten extrapulmonary localization. Infection. 2014;42(2):335\u201342.","journal-title":"Infection"},{"issue":"2","key":"10288_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10792-017-0815-9","volume":"39","author":"A Al-Qarni","year":"2019","unstructured":"Al-Qarni A, Abouammoh MA, Almousa AN, Mousa A, Abu El-Asrar AM. Presumed tuberculous uveitis in a university-based tertiary referral center in Saudi Arabia. Int Ophthalmol. 2019Feb 15;39(2):317\u201333.","journal-title":"Int Ophthalmol"},{"key":"10288_CR42","doi-asserted-by":"crossref","unstructured":"Bigdon E, Steinhorst NA, Weissleder S, Durchkiv V, St\u00fcbiger N. Treatment in Latent Tuberculosis Uveitis\u2014Is Immunosuppression Effective or Is Conventional 3-or 4-Drug Antituberculosis Therapy Mandatory? J Clin Med. 2022 May 1;11(9).","DOI":"10.3390\/jcm11092419"},{"key":"10288_CR43","doi-asserted-by":"publisher","unstructured":"Mora P, Ghirardini S, H\u00e9ron E, Sedira N, Olcelli F, Gandolfi S, et al. Ocular tuberculosis: experience of an Italian and French cohort. Acta Ophthalmol. 2015 Aug 1;93(5):e403\u20134. Available from: https:\/\/doi.org\/10.1111\/aos.12602.","DOI":"10.1111\/aos.12602"},{"issue":"9","key":"10288_CR44","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s10792-021-01886-y","volume":"41","author":"J Tsui","year":"2021","unstructured":"Tsui J, Ho M, Lui G, Li T, Chen L, Iu L, et al. The clinical presentation and treatment outcomes of ocular tuberculosis: a 5-year experience in an endemic area. Int Ophthalmol. 2021Sep 1;41(9):3199\u2013209.","journal-title":"Int Ophthalmol"},{"issue":"1","key":"10288_CR45","first-page":"11","volume":"38","author":"L Ang","year":"2018","unstructured":"Ang L, Kee A, Yeo TH, Dinesh VG, Ho SL, Teoh SC, et al. Treatment outcome in patients with presumed tubercular uveitis at a tertiary referral eye care centre in Singapore. Int Ophthalmol. 2018Feb 1;38(1):11\u20138.","journal-title":"Int Ophthalmol"},{"key":"10288_CR46","doi-asserted-by":"crossref","unstructured":"Jiang T, Zhang X, Zhou M, Jiang R, Chang Q. Prognosis of Ocular Tuberculosis Following Long-Term Antitubercular Therapy. J Ocul Pharmacol Ther. 2021;(cbr, 9511091 PG-). Available from: NS -","DOI":"10.1089\/jop.2020.0100"},{"key":"10288_CR47","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez Zamora Y, Peixoto Finamor L, P Silva LM, Rodrigues DS, Casaroli-Marano RP, Muccioli C. Clinical features and management of presumed ocular tuberculosis: A long-term follow-up cohort study in a tertiary referral center in Brazil. Eur J Ophthalmol. 2022 ;32(4):2181\u20138.","DOI":"10.1177\/11206721211044624"},{"key":"10288_CR48","doi-asserted-by":"publisher","unstructured":"Agrawal R, Agarwal A, Jabs DA, Kee A, Testi I, Mahajan S, et al. Standardization of Nomenclature for Ocular Tuberculosis\u2013Results of Collaborative Ocular Tuberculosis Study (COTS) Workshop. Ocul Immunol Inflamm. 2019;00(00):1\u201311. Available from: https:\/\/doi.org\/10.1080\/09273948.2019.1653933.","DOI":"10.1080\/09273948.2019.1653933"},{"key":"10288_CR49","doi-asserted-by":"crossref","unstructured":"Agrawal R, Gonzalez-Lopez JJ, Nobre-Cardoso J, Gupta B, Grant R, Addison PKF, et al. Predictive factors for treatment failure in patients with presumed ocular tuberculosis in an area of low endemic prevalence. Br J Ophthalmol. 2016;100(3 PG-348\u201355):348\u201355. Available from: NS -","DOI":"10.1136\/bjophthalmol-2014-306474"},{"key":"10288_CR50","doi-asserted-by":"crossref","unstructured":"Bansal R, Gupta A, Gupta V, Dogra MR, Bambery P, Arora SK. Role of Anti-Tubercular Therapy in Uveitis With Latent\/Manifest Tuberculosis. Am J Ophthalmol. 2008;146(5).","DOI":"10.1016\/j.ajo.2008.06.011"},{"key":"10288_CR51","doi-asserted-by":"crossref","unstructured":"Agrawal R, Gupta B, Gonzalez-Lopez JJ, Rahman F, Phatak S, Triantafyllopoulou I, et al. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1 PG-40\u20136):40\u20136. Available from: NS -","DOI":"10.3109\/09273948.2014.986584"},{"key":"10288_CR52","doi-asserted-by":"crossref","unstructured":"Potter J, Agrawal R, Barraclough C, Rahman F, Westcott M, Pavesio CE, et al. Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis. Ocul Immunol Inflamm. 2016;24(5 PG-508\u201314):508\u201314. Available from: NS -","DOI":"10.3109\/09273948.2015.1019155"},{"issue":"1","key":"10288_CR53","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3109\/09273948.2014.986584","volume":"23","author":"R Agrawal","year":"2015","unstructured":"Agrawal R, Gupta B, Gonzalez-Lopez JJ, Rahman F, Phatak S, Triantafyllopoulou I, et al. The role of anti-tubercular therapy in patients with presumed ocular tuberculosis. Ocul Immunol Inflamm. 2015;23(1):40\u20136.","journal-title":"Ocul Immunol Inflamm"},{"key":"10288_CR54","doi-asserted-by":"crossref","unstructured":"Indirect supportive evidence for diagnosis of tuberculosis-related uveitis: From the tuberculin skin test to the new interferon gamma release assays. Acta Ophthalmol. 2013;91(2 PG-99\u2013107):e99\u2013107. Available from: NS -","DOI":"10.1111\/j.1755-3768.2012.02564.x"},{"key":"10288_CR55","unstructured":"Khochtali S, Gargouri S, Abroug N, Ksiaa I, Attia S, Sellami D, et al. The spectrum of presumed tubercular uveitis in Tunisia, North Africa. Int Ophthalmol. 2015;35(5 PG-663\u201371):663\u201371. Available from: NS -"},{"key":"10288_CR56","doi-asserted-by":"crossref","unstructured":"Cimino L, Herbort CP, Aldigeri R, Salvarani C, Boiardi L. Tuberculous uveitis, a resurgent and underdiagnosed disease. Int Ophthalmol. 2009;29(2 PG-67\u201374):67\u201374. Available from: NS -","DOI":"10.1007\/s10792-007-9071-8"},{"key":"10288_CR57","doi-asserted-by":"crossref","unstructured":"Mao Y, Peng XY, You QS, Wang H, Zhao M, Jonas JB. Tuberculous uveitis in China. Acta Ophthalmol. 2014;92(5 PG-e393\u20137):e393\u20137. Available from: NS -","DOI":"10.1111\/aos.12351"},{"issue":"6","key":"10288_CR58","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10792-007-9170-6","volume":"28","author":"HS Al-Mezaine","year":"2008","unstructured":"Al-Mezaine HS, Al-Muammar A, Kangave D, Abu El-Asrar AM. Clinical and optical coherence tomographic findings and outcome of treatment in patients with presumed tuberculous uveitis. Int Ophthalmol. 2008;28(6):413\u201323.","journal-title":"Int Ophthalmol"},{"key":"10288_CR59","doi-asserted-by":"crossref","unstructured":"Shahidatul-Adha M, Zunaina E, Liza-Sharmini AT, Wan-Hazabbah WH, Shatriah I, Mohtar I, et al. Ocular tuberculosis in Hospital Universiti Sains Malaysia - A case series. Ann Med Surg (Lond). 2017;24(101616869 PG-25\u201330):25\u201330. Available from: NS -","DOI":"10.1016\/j.amsu.2017.10.003"},{"key":"10288_CR60","doi-asserted-by":"crossref","unstructured":"Lal B, Agrawal PK, Kapoor AK, Asthana OP, Kumar P, Prasad R, et al. Efficacy of curcumin in the management of chronic anterior uveitis. Phytotherapy Research. 1999;13(4 PG-318\u2013322):318\u201322. Available from: NS -","DOI":"10.1002\/(SICI)1099-1573(199906)13:4<318::AID-PTR445>3.0.CO;2-7"},{"issue":"1","key":"10288_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofv195","volume":"3","author":"MM Conant","year":"2016","unstructured":"Conant MM, Vrasich CR, Wongskhaluang JV, Ferenchak K, Asano MK, Becker N, et al. Role of the infectious disease consultant in management of patients with tuberculosis-associated ocular inflammation. Open Forum Infect Dis. 2016;3(1):1\u20135.","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10288_CR62","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","volume":"167","author":"D Yee","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"10288_CR63","doi-asserted-by":"crossref","unstructured":"Betzler BK, Putera I, Testi I, Nora RLD, Kempen J, MD OMK, et al. Anti-tubercular therapy in the treatment of tubercular uveitis: A systematic review and meta-analysis. Surv Ophthalmol. 2022;14:52","DOI":"10.2139\/ssrn.3938018"},{"key":"10288_CR64","doi-asserted-by":"publisher","unstructured":"Ang M, Htoon HM, Chee SP. Diagnosis of Tuberculous Uveitis: Clinical Application of an Interferon-gamma Release Assay. Ophthalmology. 2009;116(7):1391\u20136. Available from: https:\/\/doi.org\/10.1016\/j.ophtha.2009.02.005.","DOI":"10.1016\/j.ophtha.2009.02.005"},{"issue":"3","key":"10288_CR65","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjophthalmol-2011-300209","volume":"96","author":"M Ang","year":"2012","unstructured":"Ang M, Hedayatfar A, Wong W, Chee SP. Duration of anti-tubercular therapy in uveitis associated with latent tuberculosis: A case-control study. Br J Ophthalmol. 2012;96(3):332\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10288_CR66","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/bjo.2010.182659","volume":"95","author":"D Doycheva","year":"2011","unstructured":"Doycheva D, Deuter C, Hetzel J, Frick JS, Aschoff P, Schuelen E, et al. The use of positron emission tomography\/CT in the diagnosis of tuberculosis-associated uveitis. Br J Ophthalmol. 2011;95(9):1290\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10288_CR67","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12348-011-0020-3","volume":"1","author":"S Parchand","year":"2011","unstructured":"Parchand S, Tandan M, Gupta V, Gupta A. Intermediate uveitis in Indian population. J Ophthalmic Inflamm Infect. 2011Jun;1(2):65\u201370.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10288_CR68","doi-asserted-by":"crossref","unstructured":"Gupta V, Bansal R, Gupta A. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment. Am J Ophthalmol. 2011;152(5 PG-857\u201363.e2):857\u201363.e2. Available from: NS -","DOI":"10.1016\/j.ajo.2011.05.004"},{"key":"10288_CR69","doi-asserted-by":"crossref","unstructured":"Ducommun MA, Eperon S, Khonkarly MB, Cavassini M, Guex-Crosier Y. Long-term close follow-up of chorioretinal lesions in presumed ocular tuberculosis. Eur J Ophthalmol. 2012;22(2 PG-195\u2013202):195\u2013202. Available from: NS -","DOI":"10.5301\/EJO.2011.8423"},{"key":"10288_CR70","doi-asserted-by":"publisher","unstructured":"Vos AG, Wassenberg MWM, de Hoog J, Oosterheert JJ. Diagnosis and treatment of tuberculous uveitis in a low endemic setting. Int J Infect Dis. 2013;17(11):e993\u20139. Available from: https:\/\/doi.org\/10.1016\/j.ijid.2013.03.019.","DOI":"10.1016\/j.ijid.2013.03.019"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10288-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10288-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T07:23:17Z","timestamp":1737703397000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10288-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10288"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10288-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}